ABSTRACT
Background: Bevacizumab vials that are commercially available are fractionated into smaller quantities into the form of pre?filled syringes in a sterile and aseptic laboratory setting. Purpose: To share the long term experience of aliquoting of bevacizumab injections in a tertiary eye care center in India. Synopsis: Compounding of bevacizumab was found to be a cost?effective and sustainable practice that has benefited more patients with an affordable cost, while maintaining high levels of quality. Highlights: Compounding of bevacizumab, when done with aseptic precautions can be a safe and cost?effective practice, the benefits of which can be passed on to needful patients.
ABSTRACT
The Present study was made to evaluate the antiproliferative effect of chitosan extracted from crab shells against human lungadenocarcinoma cell line (A549). Chitosan was extracted from crab shells which includes deproteinization, demineralization,deacetylation. MTT method to find out the toxicity and cell viability of chitosan in both normal and cancer cells (A549). The Propidiumiodide staining and DNA fragmentation is to analyze the apoptotic bodies in A549 cell line. Chitosan appeared creamy white in colourand the total carbohydrate content was estimated as 0.07 mg/ml. The antiproliferative effect of chitosan against A549 cells clearlyemphasizes, that there is a decrease in the cell viability. The 50 % inhibition (IC50) of the cell growth was found at 20 µg/ml.The cytolocalization of nuclear morphology and DNA fragmentation assay revealed the induction of apoptotic cell death in A549 at 24 hours.Chitosan exhibits the inhibitory effect by inducing loss of cell viability, morphology change and DNA fragmentation in A549 cells due tothe presence of free protonated amino groups on the polymer chain. Our preliminary studies support that chitosan could be an efficienttherapeutic agent for cancer